Imunon has announced the alignment of the FDA with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol.

Research reveals men skipping prostate cancer screenings are 45% more likely to die from the disease. Evidence from a large European study indicates P ...

The presence of biomarkers, even in small amounts, can shape the course of treatment for a patient, says Andy Guinigundo, MSN, RN, CNP, ANP-BC.

Helen Ready’s 1971 women’s liberation anthem, “I Am Woman Hear Me Roar,” comes to mind when I think of Purim. Remember Esther ...

Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection this weekend, leading to customer concerns about ...